

# ICMJE DISCLOSURE FORM

**Date: June 29, 2022**

**Your Name: Maria Ruth B. Pineda-Cortel**

**Manuscript Title: Cut-off Points of 75-Gram Oral Glucose Tolerance Test as a Diagnostic Test for Gestational Diabetes Mellitus in Pregnant Filipino Population**

**Manuscript number (if known): JLPM-22-26-CL**

**In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.**

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

**In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.**

[illegible]


| Time frame: past 36 months |  |      |  |
|----------------------------|--|------|--|
| 2                          | Grants or contracts from any entity (if not indicated in item #1 above).                                     | None |  |
|                            |  |      |  |
|                            |  |      |  |
| 3                          | Royalties or licenses  | None |  |
|                            |  |      |  |
|                            |  |      |  |
| 4                          | Consulting fees  | None |  |
|                            |  |      |  |
|                            |  |      |  |
| 5                          | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None |  |
|                            |  |      |  |
|                            |  |      |  |
| 6                          | Payment for expert testimony   | None |  |
|                            |  |      |  |
|                            |  |      |  |
| 7                          | Support for attending meetings and/or travel   | None |  |
|                            |  |      |  |
|                            |  |      |  |
| 8                          | Patents planned, issued or pending   | None |  |
|                            |  |      |  |
|                            |  |      |  |
| 9                          | Participation on a Data Safety Monitoring Board or Advisory Board  | None |  |
|                            |  |      |  |
|                            |  |      |  |
| 10                         | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid            | None |  |
|                            |  |      |  |
|                            |  |      |  |
| 11                         | Stock or stock options   | None |  |
|                            |  |      |  |
|                            |  |      |  |
| 12                         | Receipt of equipment, materials, drugs, medical writing, gifts or other services                             | None |  |
|                            |  |      |  |
|                            |  |      |  |
| 13                         | Other financial or non-financial interests   | None |  |
|                            |  |      |  |
|                            |  |      |  |

**Please summarize the above conflict of interest in the following box:**

The authors declare no conflict of interest. Funding agency of this project was mentioned in the acknowledgement section of the paper.

Please place an "X" next to the following statement to indicate your agreement:

  X   I certify that I have answered every question and have not altered the wording of any of the questions on this form.

A handwritten signature in dark ink, appearing to read 'M. Pineda-Cortel', with a large, loopy flourish above it.

Assoc. Prof. Maria Ruth B. Pineda-Cortel, Ph.D

# ICMJE DISCLOSURE FORM

Date: June 29, 2022

Your Name: Therese Suratos

Manuscript Title: Cut-off Points of 75-Gram Oral Glucose Tolerance Test as a Diagnostic Test for Gestational Diabetes Mellitus in Pregnant Filipino Population

Manuscript number (if known): JLPM-22-26-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   |  | Name all entities with whom you have this relationship or indicate none (add rows as needed)                  | Specifications/Comments (e.g., if payments were made to you or to your institution)  |
|---|--|---|--|
| <b>Time frame: Since the initial planning of the work</b> |  |   |  |
| 1   | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)<br><b>No time limit for this item.</b> | Department of Science and Technology – Philippine Council for Health Research and Development (DOST – PCHRD). | Department of Science and Technology – Philippine Council for Health Research and Development (DOST – PCHRD). This publication was part of the "Gestational Diabetes Mellitus Study" on potential identification of early biomarkers of the disease (grant project number 18-0200) supported and funded by DOST-PCHRD. |
|   |  |   |  |
|   |  |   |  |
|   |  |   |  |
|   |  |   |  |
|   |  |   |  |
|   |  |   |  |
| <b>Time frame: past 36 months</b>                         |  |   |  |
| 2   | Grants or contracts from   | None  |  |


|    |  |          |  |
|----|--|----------|--|
|    | any entity (if not indicated in item #1 above).  |          |  |
| 3  | Royalties or licenses  | ___ None |  |
|    |  |          |  |
|    |  |          |  |
| 4  | Consulting fees  | ___ None |  |
|    |  |          |  |
|    |  |          |  |
| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ___ None |  |
|    |  |          |  |
|    |  |          |  |
| 6  | Payment for expert testimony   | ___ None |  |
|    |  |          |  |
|    |  |          |  |
| 7  | Support for attending meetings and/or travel   | ___ None |  |
|    |  |          |  |
|    |  |          |  |
| 8  | Patents planned, issued or pending   | ___ None |  |
|    |  |          |  |
|    |  |          |  |
| 9  | Participation on a Data Safety Monitoring Board or Advisory Board  | ___ None |  |
|    |  |          |  |
|    |  |          |  |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid            | ___ None |  |
|    |  |          |  |
|    |  |          |  |
| 11 | Stock or stock options   | ___ None |  |
|    |  |          |  |
|    |  |          |  |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services                             | ___ None |  |
|    |  |          |  |
|    |  |          |  |
| 13 | Other financial or non-financial interests   | ___ None |  |
|    |  |          |  |
|    |  |          |  |

**Please summarize the above conflict of interest in the following box:**

The authors declare no conflict of interest. Funding agency of this project was mentioned in the acknowledgement section of the paper.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

A handwritten signature in black ink, appearing to read 'T. Suratos', written over the printed name.

Ms. Therese Suratos

# ICMJE DISCLOSURE FORM

Date: June 29, 2022

Your Name: Therriz Mae P. Mamerto

Manuscript Title: Cut-off Points of 75-Gram Oral Glucose Tolerance Test as a Diagnostic Test for Gestational Diabetes Mellitus in Pregnant Filipino Population

Manuscript number (if known): JLPM-22-26-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   |  | Name all entities with whom you have this relationship or indicate none (add rows as needed)                  | Specifications/Comments (e.g., if payments were made to you or to your institution)  |
|---|--|---|--|
| <b>Time frame: Since the initial planning of the work</b> |  |   |  |
| 1   | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)<br><b>No time limit for this item.</b> | Department of Science and Technology – Philippine Council for Health Research and Development (DOST – PCHRD). | Department of Science and Technology – Philippine Council for Health Research and Development (DOST – PCHRD). This publication was part of the "Gestational Diabetes Mellitus Study" on potential identification of early biomarkers of the disease (grant project number 18-0200) supported and funded by DOST-PCHRD. |
|   |  |   |  |
|   |  |   |  |
|   |  |   |  |
|   |  |   |  |
|   |  |   |  |
|   |  |   |  |
| <b>Time frame: past 36 months</b>                         |  |   |  |
| 2   | Grants or contracts from   | None  |  |

|    |  |          |  |
|----|--|----------|--|
|    | any entity (if not indicated in item #1 above).  |          |  |
| 3  | Royalties or licenses  | ___ None |  |
|    |  |          |  |
|    |  |          |  |
| 4  | Consulting fees  | ___ None |  |
|    |  |          |  |
|    |  |          |  |
| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ___ None |  |
|    |  |          |  |
|    |  |          |  |
| 6  | Payment for expert testimony   | ___ None |  |
|    |  |          |  |
|    |  |          |  |
| 7  | Support for attending meetings and/or travel   | ___ None |  |
|    |  |          |  |
|    |  |          |  |
| 8  | Patents planned, issued or pending   | ___ None |  |
|    |  |          |  |
|    |  |          |  |
| 9  | Participation on a Data Safety Monitoring Board or Advisory Board  | ___ None |  |
|    |  |          |  |
|    |  |          |  |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid            | ___ None |  |
|    |  |          |  |
|    |  |          |  |
| 11 | Stock or stock options   | ___ None |  |
|    |  |          |  |
|    |  |          |  |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services                             | ___ None |  |
|    |  |          |  |
|    |  |          |  |
| 13 | Other financial or non-financial interests   | ___ None |  |
|    |  |          |  |
|    |  |          |  |

**Please summarize the above conflict of interest in the following box:**

The authors declare no conflict of interest. Funding agency of this project was mentioned in the acknowledgement section of the paper.



Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

A handwritten signature in black ink, appearing to read 'Therriz Mae R. Mamerto', written in a cursive style.

Ms. Therriz Mae R. Mamerto, MSc Biomedsci